FDA OKs ZIOPHARM Oncology Inc.’s (ZIOP) New Drug Application for DNA-based Therapeutic Candidate
ZIOPHARM Oncology Inc., a biopharm company engaged in the development and commercialization of a diverse portfolio of cancer therapeutics, Friday announced that the U.S. Food & Drug Administration (FDA) has accepted the company’s investigational new drug (IND) application, giving the company the go-ahead to commence clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate. RJ Kirk, Intrexon's chairman and CEO, and a director of the ZIOPHARM board of directors, said the quick approval of the IND reflects the company’s strength in DNA-based therapeutics in oncology. ZIOPHARM is focusing on pursuing the development of novel DNA-based therapeutics for oncology pursuant…